Skip to main content

NASDAQ:HRTX - Heron Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.00
  • Forecasted Upside: 56.34 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$16.63
▼ -0.09 (-0.54%)
1 month | 3 months | 12 months
Get New Heron Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HRTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$26.00
▲ +56.34% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Heron Therapeutics in the last 3 months. The average price target is $26.00, with a high forecast of $35.00 and a low forecast of $21.00. The average price target represents a 56.34% upside from the last price of $16.63.

Buy

The current consensus among 5 investment analysts is to buy stock in Heron Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/2/2020SVB LeerinkBoost Price TargetOutperform$21.00 ➝ $24.00Medium
i
9/8/2020Stifel NicolausReiterated RatingBuyMedium
i
Rating by Derek Archila at Stifel Nicolaus
8/6/2020Northland SecuritiesInitiated CoverageBuy$35.00Medium
i
Rating by Carl Byrnes at Northland Securities
8/6/2020Stifel NicolausReiterated RatingBuy$21.00Medium
i
Rating by Derek Archila at Stifel Nicolaus
6/30/2020SVB LeerinkLower Price TargetOutperform$26.00 ➝ $19.00Low
i
6/29/2020Stifel NicolausInitiated CoverageBuy$21.00Medium
i
Rating by Derek Archila at Stifel Nicolaus
6/22/2020Northland SecuritiesInitiated CoverageBuy$47.00High
i
Rating by Carl Byrnes at Northland Securities
5/26/2020GuggenheimInitiated CoverageBuy$24.00Medium
i
5/18/2020FIXInitiated CoverageAddLow
i
5/6/2020Stifel NicolausReiterated RatingBuy$29.00Medium
i
Rating by Derek Archila at Stifel Nicolaus
4/15/2020Needham & Company LLCReiterated RatingBuy$44.00High
i
3/2/2020Stifel NicolausReiterated RatingBuy$29.00Low
i
Rating by Derek Archila at Stifel Nicolaus
3/2/2020Needham & Company LLCLower Price TargetBuy$48.00 ➝ $44.00High
i
2/20/2020Cantor FitzgeraldReiterated RatingBuy$41.00N/A
i
Rating by Brandon Folkes at Cantor Fitzgerald
2/20/2020Needham & Company LLCLower Price TargetBuy$50.00 ➝ $48.00High
i
1/15/2020CowenReiterated RatingBuy$40.00Low
i
11/13/2019Northland SecuritiesReiterated RatingBuy$47.00High
i
11/12/2019SVB LeerinkReiterated RatingOutperformMedium
i
Rating by A. Fadia at SVB Leerink LLC
10/3/2019JMP SecuritiesLower Price TargetOutperform ➝ Market Outperform$38.00 ➝ $32.00High
i
10/1/2019JMP SecuritiesReiterated RatingOutperform$33.00 ➝ $38.00High
i
10/1/2019CowenReiterated RatingBuy$40.00High
i
8/13/2019Evercore ISIReiterated RatingBuy$75.00Low
i
8/5/2019Stifel NicolausReiterated RatingBuy$38.00Low
i
Rating by Derek Archila at Stifel Nicolaus
8/5/2019Northland SecuritiesReiterated RatingBuy$55.00Low
i
Rating by Carl Byrnes at Northland Securities
5/9/2019CowenReiterated RatingBuyMedium
i
5/9/2019Northland SecuritiesReiterated RatingBuy$55.00High
i
Rating by Carl Byrnes at Northland Securities
5/1/2019Stifel NicolausReiterated RatingBuy$38.00High
i
Rating by Derek Archila at Stifel Nicolaus
4/2/2019Northland SecuritiesSet Price TargetBuy$55.00High
i
Rating by Carl Byrnes at Northland Securities
3/11/2019Northland SecuritiesReiterated RatingBuyMedium
i
3/4/2019Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
i
Rating by B. Folkes at Cantor Fitzgerald
2/22/2019Cantor FitzgeraldSet Price TargetBuy$50.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
2/22/2019Stifel NicolausReiterated RatingBuy$54.00Low
i
1/16/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00 ➝ $64.00Medium
i
12/31/2018Cantor FitzgeraldReiterated RatingBuy$50.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
10/30/2018Cantor FitzgeraldSet Price TargetBuy$50.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
9/27/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
i
Rating by Louise Chen at Cantor Fitzgerald
9/21/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
9/13/2018Stifel NicolausInitiated CoverageBuy$55.00Low
i
8/8/2018Cantor FitzgeraldReiterated RatingBuy$50.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
7/19/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$40.00 ➝ $50.00High
i
Rating by Louise Chen at Cantor Fitzgerald
6/22/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$34.00 ➝ $50.00Medium
i
Rating by Christopher Liu at Oppenheimer Holdings Inc.
6/22/2018SVB LeerinkBoost Price TargetOutperform$46.00High
i
Rating by A. Fadia at SVB Leerink LLC
6/22/2018MizuhoReiterated RatingBuy$41.00High
i
6/21/2018CowenReiterated RatingBuy$54.00High
i
6/21/2018Needham & Company LLCBoost Price TargetBuy ➝ Positive$66.00Medium
i
6/21/2018Cantor FitzgeraldReiterated RatingBuy$40.00High
i
Rating by Louise Chen at Cantor Fitzgerald
6/21/2018Evercore ISIBoost Price TargetOutperform$56.00 ➝ $80.00High
i
5/24/2018Cantor FitzgeraldSet Price TargetBuy$40.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
5/10/2018OppenheimerSet Price TargetBuy$34.00High
i
Rating by Christopher Liu at Oppenheimer Holdings Inc.
5/10/2018Cantor FitzgeraldSet Price TargetBuy$40.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
5/8/2018CowenReiterated RatingBuy$48.00Low
i
4/22/2018Cantor FitzgeraldSet Price TargetBuy$40.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
4/6/2018Cantor FitzgeraldSet Price TargetBuy$40.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
4/5/2018Evercore ISIInitiated CoverageOutperform$56.00Medium
i
4/5/2018Lake Street CapitalSet Price TargetBuy$42.00Medium
i
Rating by Bruce Jackson at Lake Street Capital
3/27/2018OppenheimerSet Price TargetBuy$34.00Low
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
3/26/2018Northland SecuritiesReiterated RatingBuy$55.00Low
i
3/21/2018Noble FinancialReiterated RatingBuyLow
i
Rating by Caroline Palomeque at Noble Financial
3/20/2018Needham & Company LLCBoost Price TargetBuy$42.00Medium
i
3/19/2018CowenReiterated RatingBuyMedium
i
3/19/2018OppenheimerSet Price TargetBuy$34.00Low
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
3/19/2018MizuhoReiterated RatingBuy ➝ Buy$28.00 ➝ $35.00High
i
3/19/2018Cantor FitzgeraldSet Price TargetBuy$40.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
3/2/2018Noble FinancialReiterated RatingBuyHigh
i
Rating by Caroline Palomeque at Noble Financial
3/1/2018OppenheimerSet Price TargetBuy$27.00Low
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
3/1/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $30.00High
i
2/27/2018Cantor FitzgeraldSet Price TargetBuy$31.00High
i
Rating by Louise Chen at Cantor Fitzgerald
2/16/2018Lake Street CapitalSet Price TargetBuy$42.00Low
i
Rating by Bruce Jackson at Lake Street Capital
2/15/2018Cantor FitzgeraldSet Price TargetBuy$31.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
1/16/2018MizuhoReiterated RatingBuy$28.00Low
i
1/15/2018Cantor FitzgeraldSet Price TargetBuy$31.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
1/5/2018Cantor FitzgeraldSet Price TargetBuy$31.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
1/2/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$22.00High
i
Rating by A. Fadia at SVB Leerink LLC
12/14/2017OppenheimerSet Price TargetBuy$27.00Low
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
12/8/2017MizuhoReiterated RatingBuy$28.00Medium
i
12/6/2017CowenReiterated RatingBuy$40.00Medium
i
Rating by Boris Peaker at Cowen Inc
11/12/2017Noble FinancialReiterated RatingBuyN/A
i
Rating by Kumaraguru Raja at Noble Financial
11/10/2017OppenheimerReiterated RatingBuy$27.00N/A
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
11/7/2017MizuhoReiterated RatingBuy$28.00N/A
i
11/6/2017CowenReiterated RatingBuy$40.00N/A
i
Rating by Boris Peaker at Cowen Inc
11/2/2017Cantor FitzgeraldReiterated RatingBuy$31.00N/A
i
Rating by Louise Chen at Cantor Fitzgerald
10/30/2017OppenheimerInitiated CoverageBuy$27.00N/A
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
10/26/2017Cantor FitzgeraldSet Price TargetBuy$31.00N/A
i
Rating by Louise Chen at Cantor Fitzgerald
10/20/2017Cantor FitzgeraldSet Price TargetBuy$31.00N/A
i
Rating by Louise Chen at Cantor Fitzgerald
10/6/2017Noble FinancialReiterated RatingBuy$24.00N/A
i
Rating by Kumaraguru Raja at Noble Financial
9/27/2017Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$40.00Low
i
9/26/2017MizuhoInitiated CoverageBuy$28.00Low
i
9/25/2017Cantor FitzgeraldReiterated RatingBuyMedium
i
Rating by Louise Chen at Cantor Fitzgerald
8/18/2017Cantor FitzgeraldSet Price TargetBuy$31.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
8/16/2017Jefferies Financial GroupReiterated RatingBuyLow
i
8/10/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Kumaraguru Raja at Noble Financial
8/3/2017CowenSet Price TargetBuy$40.00Low
i
Rating by Boris Peaker at Cowen Inc
7/18/2017AegisReiterated RatingBuy$33.00Low
i
Rating by J. Wittes at Aegis
7/14/2017Jefferies Financial GroupReiterated RatingBuy$26.00Low
i
6/26/2017Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by L. Chen at Cantor Fitzgerald
5/26/2017CowenReiterated RatingBuy$40.00High
i
5/12/2017Noble FinancialReiterated RatingBuyMedium
i
5/11/2017Cantor FitzgeraldReiterated RatingBuy$30.00 ➝ $31.00Medium
i
Rating by Chiara Russo at Cantor Fitzgerald
4/10/2017Jefferies Financial GroupReiterated RatingBuy$29.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
3/21/2017AegisReiterated RatingBuyMedium
i
Rating by J. Wittes at Aegis
2/27/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$28.00N/A
i
2/26/2017Cantor FitzgeraldSet Price TargetBuy$34.00 ➝ $30.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
1/12/2017Cantor FitzgeraldSet Price TargetBuy$34.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
1/6/2017Cantor FitzgeraldReiterated RatingOverweight$34.00N/A
i
1/6/2017CowenReiterated RatingBuy$40.00N/A
i
Rating by Boris Peaker at Cowen Inc
1/5/2017Jefferies Financial GroupSet Price TargetBuy$40.00 ➝ $29.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
1/5/2017SVB LeerinkSet Price TargetBuy$21.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
12/11/2016CowenReiterated RatingBuy$40.00N/A
i
Rating by Boris Peaker at Cowen Inc
11/10/2016Cantor FitzgeraldReiterated RatingBuy$34.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
11/9/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Liisa Bayko at JMP Securities
10/26/2016AegisInitiated CoverageBuy$41.00N/A
i
10/8/2016SVB LeerinkSet Price TargetBuy$34.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
10/4/2016Brean CapitalInitiated CoverageBuy$41.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
10/3/2016Jefferies Financial GroupLower Price TargetBuy$46.00 ➝ $40.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
10/2/2016SVB LeerinkReiterated RatingBuy$33.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
9/9/2016JMP SecuritiesReiterated RatingBuyN/A
i
9/6/2016Lake Street CapitalReiterated RatingBuy$45.00N/A
i
Rating by B. Jackson at Lake Street Capital
8/18/2016SVB LeerinkReiterated RatingOutperform$33.00N/A
i
Rating by jason gerberry at SVB Leerink LLC
8/13/2016Brean CapitalReiterated RatingBuy$55.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
8/11/2016SVB LeerinkSet Price TargetBuy$33.00N/A
i
Rating by jason gerberry at SVB Leerink LLC
8/9/2016Cantor FitzgeraldReiterated RatingBuy$38.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
8/3/2016Cantor FitzgeraldReiterated RatingBuy$41.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
7/27/2016Jefferies Financial GroupReiterated RatingBuy$46.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
7/9/2016CowenReiterated RatingBuyN/A
i
Rating by Boris Peaker at Cowen Inc
6/27/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
6/24/2016Cantor FitzgeraldReiterated RatingBuy$41.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
(Data available from 5/9/2016 forward)
Heron Therapeutics logo
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $16.63
$16.53
$17.29

50 Day Range

MA: $16.73
$14.49
$18.40

52 Week Range

Now: $16.63
$12.52
$22.40

Volume

737,823 shs

Average Volume

1,017,376 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Heron Therapeutics?

The following Wall Street research analysts have issued research reports on Heron Therapeutics in the last twelve months: FIX, Guggenheim, Northland Securities, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for HRTX.

What is the current price target for Heron Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Heron Therapeutics in the last year. Their average twelve-month price target is $26.00, suggesting a possible upside of 56.3%. Northland Securities has the highest price target set, predicting HRTX will reach $35.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $21.00 for Heron Therapeutics in the next year.
View the latest price targets for HRTX.

What is the current consensus analyst rating for Heron Therapeutics?

Heron Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HRTX will outperform the market and that investors should add to their positions of Heron Therapeutics.
View the latest ratings for HRTX.

What other companies compete with Heron Therapeutics?

How do I contact Heron Therapeutics' investor relations team?

Heron Therapeutics' physical mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is 858-251-4400 and its investor relations email address is [email protected] The official website for Heron Therapeutics is www.herontx.com.